NewAmsterdam Pharma announced the appointment of Maryellen McQuade as the company’s new Chief People Officer. This executive appointment is a strategic step as the company continues to expand its operations and prepare for potential commercialization.
Ms. McQuade received inducement share options covering 170,800 of NewAmsterdam’s ordinary shares and restricted stock units covering 36,600 ordinary shares. These grants were made as an inducement material to her acceptance of employment.
The addition of a Chief People Officer strengthens the executive leadership team, focusing on talent acquisition, development, and retention, which are critical for building the necessary infrastructure to support a future product launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.